Why isn't there separate SaaS pricing for developing countries?

Many founders assume “developing countries should pay less” is an obvious win-win. In practice, separate SaaS pricing by country is hard to sustain, easy to exploit, and sometimes incompatible with how healthcare buyers, regulators, and channel partners operate. The result: many SaaS companies default to one global list price (or only mild regional adjustments), even when they genuinely want to expand access.

1) Arbitrage: the simplest reason it breaks

Arbitrage means customers find a way to buy at the cheaper price and use it in the higher-priced market. With software, arbitrage is easier than with physical goods because delivery is digital and marginal cost is low.

• Account hopping: A US or EU clinic signs up using an address, reseller, or subsidiary in a lower-priced country.
• Cross-border groups: Hospital systems with international footprints pressure you to extend the lowest price to all sites.
• Consultants and BPOs: Third parties buy “cheap seats” and resell services bundled with implementation.

To prevent arbitrage you need enforcement: identity verification, geo-restrictions, contract audits, and legal follow-up. That enforcement costs money and can create a poor user experience—especially in healthcare where onboarding already involves security reviews, BAAs (in the US), and IT approvals.

2) Healthcare procurement punishes “unfair” price differences

In medtech, you’re rarely selling to an individual; you’re selling to a procurement process. Procurement teams compare prices across vendors and across regions, and they often have internal rules that make large price gaps painful.

• Reference pricing: A buyer uses the lowest known price as a benchmark and demands “most favored” terms.
• Group purchasing and tenders: In many countries, hospitals buy through tenders or centralized purchasing. If your pricing looks inconsistent, you can be disqualified or forced into a race to the bottom.
• Public sector scrutiny: Government hospitals may require justification for pricing. If your global pricing story isn’t coherent, it becomes a compliance and reputational risk.

Even if your intent is access, procurement can interpret it as price discrimination. The safest path for many vendors is a single list price plus negotiated discounts under clear, auditable rules.

3) Support, implementation, and compliance costs don’t scale down with GDP

Founders often think “lower-income market = lower cost to serve.” In enterprise healthcare SaaS, the opposite can be true.

What drives cost-to-serve in medtech SaaS

• Integration work: HL7/FHIR interfaces, SSO, EHR integration, data migration, and workflow customization. These are labor-heavy and not cheaper just because the hospital is in a lower-GDP country.
• Security and privacy: Threat modeling, penetration testing, audit trails, encryption, access controls, and incident response. Requirements vary by jurisdiction, but the engineering effort is real everywhere.
• Clinical validation: If your product influences care, you may need local clinical evaluation, IRB approval for studies, and ongoing post-market surveillance processes (even if the exact regulatory framework differs from FDA).
• Training and change management: Clinicians need onboarding, protocols, and sometimes multilingual materials.

So if you cut price aggressively without reducing cost-to-serve, you can end up subsidizing every deployment—fine for a pilot, deadly as a business model.

4) Regulatory and liability realities: “software” can still be medical device

In medtech, pricing strategy can’t be separated from regulatory strategy. If your SaaS is considered Software as a Medical Device (SaMD) or part of a regulated workflow, you may face additional obligations that make “low price” hard to justify.

• FDA pathway (US): Depending on claims and risk, you may be in 510(k), De Novo, or PMA territory. The cost of maintaining quality systems, documentation, and post-market processes is not region-specific.
• Labeling and intended use: If you sell a “clinical decision support” feature in one market but market it as “analytics” elsewhere to justify different pricing, you risk inconsistent claims and regulatory exposure.
• Liability and insurance: If something goes wrong, plaintiffs’ attorneys won’t care that you priced it cheaply in one geography.

Many companies keep product scope and claims consistent globally to reduce regulatory complexity—then pricing tends to follow that uniformity.

5) Reimbursement and ROI differ more than income levels

In healthcare, willingness to pay is often tied to reimbursement (how providers get paid) and budget structures, not just GDP per capita.

• US dynamics: A product that helps capture revenue (e.g., documentation improvement) or reduces penalties can justify higher pricing. Some products map to CPT codes or support billable services; others don’t. If there’s no reimbursement lever, pricing must come from cost savings or quality metrics.
• Single-payer systems: Budgets can be centralized and constrained; adoption may depend on national guidelines, HTA (health technology assessment), or tender cycles.
• Private hospital chains: In some “developing” markets, top-tier private hospitals have budgets comparable to mid-tier Western hospitals and expect enterprise-grade support.

So a simple “developing vs developed” price split is often the wrong segmentation. The better segmentation is: ability to realize ROI and budget authority (e.g., private tertiary hospital vs rural clinic) plus cost-to-serve (integration-heavy vs standalone).

6) Better alternatives: access-friendly pricing that doesn’t implode

If you want equitable pricing without creating a loophole, use structures that tie price to verifiable constraints and cost-to-serve, not just geography.

A) Tier by facility type and use case (not country)

• Clinic tier: limited integrations, smaller user caps, self-serve onboarding.
• Hospital tier: integrations, audit logs, advanced admin controls, SLA.
• Enterprise tier: multi-site, custom security review, dedicated CSM, uptime guarantees.

This is defensible because the product and service levels differ. Procurement understands paying more for more.

B) Separate “license” from “services” explicitly

Many pricing fights come from bundling. Consider:

• Software subscription: lower, standardized, globally consistent.
• Implementation/integration: priced based on scope (interfaces, sites, data migration).
• Support SLA: optional paid add-on.

This lets you offer lower entry pricing in resource-constrained settings without silently eating high implementation costs.

C) Use eligibility-based discounts with auditability

If you do want regional affordability, make it rule-based:

• Nonprofit / academic discounts with documentation.
• Public hospital pricing tied to tender terms.
• Humanitarian/access programs with contractual restrictions (no resale, limited sites, annual verification).

This reduces arbitrage because the discount is linked to an entity type and contract terms, not just an IP address.

D) Consider outcome- or volume-based pricing where feasible

In medtech SaaS, you can sometimes price per study, per bed, per clinician, per patient monitored, or per procedure. That naturally scales with usage and budget size. Be careful: if your product is regulated SaMD, ensure your pricing metric doesn’t incentivize unsafe use or conflict with intended use.

Rule of thumb: if you can’t enforce the boundary (who qualifies, where it can be used, and what support is included), geographic pricing will leak and eventually converge to the lowest price.

What to do next

1. Write your segmentation in one page: define 3 customer tiers by facility type, integration needs, and decision-maker (clinical champion vs IT vs procurement).
2. Unbundle your offer: separate subscription, implementation, and SLA support so you can lower entry price without subsidizing deployments.
3. Create an “access discount policy”: eligibility criteria, required documents, audit rights, and resale restrictions—so discounts are defensible in procurement.
4. Pressure-test against arbitrage: ask “How would a US/EU buyer get the lowest price?” and close the loopholes contractually (and operationally).
5. Sanity-check regulatory messaging: ensure your claims and intended use are consistent across markets (especially if you’re on a 510(k), De Novo, or PMA path in the US).